Risk profile for antiangiogenic agent-related osteonecrosis of the jaws

Detalhes bibliográficos
Autor(a) principal: Caminha,Raquel D’Aquino Garcia
Data de Publicação: 2019
Outros Autores: Chicrala,Gabriela Moura, Soares Júnior,Luiz Alberto Valente, Santos,Paulo Sérgio da Silva
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Einstein (São Paulo)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000300400
Resumo: ABSTRACT To establish the profile of patients who developed antiangiogenic agent-related osteonecrosis of the jaws, and identify the treatments currently used in dental management. We searched the PubMed®/Medline® and Scopus databases using the words “osteonecrosis AND antiangiogenic therapy”, with the following inclusion criteria: articles published in English, case reports, available online, and for an unlimited period. Of the 209 articles retrieved, 18 were selected, for a total of 19 case reports, since one article included two cases that met the inclusion criteria for this study. Medication-related osteonecrosis of the jaws is characterized by exposure of necrotic bone in the oral cavity that does not heal over a period of 8 weeks in patients with no previous history of radiation therapy. Antiangiogenic drugs are indicated in the treatment of certain tumors, since they stop the formation of new blood vessels, controlling tumor growth and the chance of metastasis. Dental prevention is essential in patients who will be put on antiangiogenic agents, to minimize the risk for osteonecrosis.
id IIEPAE-1_d684ed97f32fe84e895e44aa845c23ff
oai_identifier_str oai:scielo:S1679-45082019000300400
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling Risk profile for antiangiogenic agent-related osteonecrosis of the jawsOsteonecrosisDental careMetastatic neoplasmAngiogenesis inhibitorsAntineoplastic agentsABSTRACT To establish the profile of patients who developed antiangiogenic agent-related osteonecrosis of the jaws, and identify the treatments currently used in dental management. We searched the PubMed®/Medline® and Scopus databases using the words “osteonecrosis AND antiangiogenic therapy”, with the following inclusion criteria: articles published in English, case reports, available online, and for an unlimited period. Of the 209 articles retrieved, 18 were selected, for a total of 19 case reports, since one article included two cases that met the inclusion criteria for this study. Medication-related osteonecrosis of the jaws is characterized by exposure of necrotic bone in the oral cavity that does not heal over a period of 8 weeks in patients with no previous history of radiation therapy. Antiangiogenic drugs are indicated in the treatment of certain tumors, since they stop the formation of new blood vessels, controlling tumor growth and the chance of metastasis. Dental prevention is essential in patients who will be put on antiangiogenic agents, to minimize the risk for osteonecrosis.Instituto Israelita de Ensino e Pesquisa Albert Einstein2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000300400einstein (São Paulo) v.17 n.3 2019reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.31744/einstein_journal/2019rw4628info:eu-repo/semantics/openAccessCaminha,Raquel D’Aquino GarciaChicrala,Gabriela MouraSoares Júnior,Luiz Alberto ValenteSantos,Paulo Sérgio da Silvaeng2019-07-19T00:00:00Zoai:scielo:S1679-45082019000300400Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2019-07-19T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
title Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
spellingShingle Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
Caminha,Raquel D’Aquino Garcia
Osteonecrosis
Dental care
Metastatic neoplasm
Angiogenesis inhibitors
Antineoplastic agents
title_short Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
title_full Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
title_fullStr Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
title_full_unstemmed Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
title_sort Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
author Caminha,Raquel D’Aquino Garcia
author_facet Caminha,Raquel D’Aquino Garcia
Chicrala,Gabriela Moura
Soares Júnior,Luiz Alberto Valente
Santos,Paulo Sérgio da Silva
author_role author
author2 Chicrala,Gabriela Moura
Soares Júnior,Luiz Alberto Valente
Santos,Paulo Sérgio da Silva
author2_role author
author
author
dc.contributor.author.fl_str_mv Caminha,Raquel D’Aquino Garcia
Chicrala,Gabriela Moura
Soares Júnior,Luiz Alberto Valente
Santos,Paulo Sérgio da Silva
dc.subject.por.fl_str_mv Osteonecrosis
Dental care
Metastatic neoplasm
Angiogenesis inhibitors
Antineoplastic agents
topic Osteonecrosis
Dental care
Metastatic neoplasm
Angiogenesis inhibitors
Antineoplastic agents
description ABSTRACT To establish the profile of patients who developed antiangiogenic agent-related osteonecrosis of the jaws, and identify the treatments currently used in dental management. We searched the PubMed®/Medline® and Scopus databases using the words “osteonecrosis AND antiangiogenic therapy”, with the following inclusion criteria: articles published in English, case reports, available online, and for an unlimited period. Of the 209 articles retrieved, 18 were selected, for a total of 19 case reports, since one article included two cases that met the inclusion criteria for this study. Medication-related osteonecrosis of the jaws is characterized by exposure of necrotic bone in the oral cavity that does not heal over a period of 8 weeks in patients with no previous history of radiation therapy. Antiangiogenic drugs are indicated in the treatment of certain tumors, since they stop the formation of new blood vessels, controlling tumor growth and the chance of metastasis. Dental prevention is essential in patients who will be put on antiangiogenic agents, to minimize the risk for osteonecrosis.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000300400
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000300400
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.31744/einstein_journal/2019rw4628
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.17 n.3 2019
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129909679980544

Registros relacionados